Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells

https://doi.org/10.1016/j.bmcl.2013.09.037Get rights and content

Abstract

An analysis of the main pharmacophoric features present in the still limited number of inhibitors of glucose transporter GLUT1 led to the identification of new oxime-based inhibitors, which proved to be able to efficiently hinder glucose uptake and cell growth in H1299 lung cancer cells. The most important interactions of a representative inhibitor were indicated by a novel computational model of GLUT1, which was purposely developed to explain these results and to provide useful indications for the design and the development of new and more efficient GLUT1 inhibitors.

Section snippets

Acknowledgments

We gratefully acknowledge the support from the University of Pisa (intramural research funds). This study was partially supported by the Edison Program of the State of Ohio and Ohio University Heritage College of Osteopathic Medicine.

References and notes (30)

  • D. Hanahan et al.

    Cell

    (2011)
  • S. Rastogi et al.

    Cancer Lett.

    (2007)
  • Y. Liu et al.

    Cancer Lett.

    (2010)
  • W. Zhang et al.

    Bioorg. Med. Chem. Lett.

    (2010)
  • S. Bertini et al.

    Eur. J. Med. Chem.

    (2011)
  • S. Wei et al.

    J. Biol. Chem.

    (2010)
  • B.M. Collins et al.

    Steroids

    (1997)
  • F.A. Zuniga et al.

    J. Biol. Chem.

    (2001)
  • C. Granchi et al.

    ChemMedChem

    (2012)
  • S. Ben-Haim et al.

    J. Nucl. Med.

    (2009)
  • T. Amann et al.

    Expert Opin. Ther. Targets

    (2009)
  • M. Younes et al.

    Cancer

    (1997)
  • D.A. Chan et al.

    Sci. Transl. Med.

    (2011)
  • K. Tsujihara et al.

    Chem. Pharm. Bull.

    (1996)
  • Y. Liu et al.

    Mol. Cancer Ther.

    (2012)
  • Cited by (41)

    • Isosteres of ester derived glucose uptake inhibitors

      2020, Bioorganic and Medicinal Chemistry Letters
    • Synthesis of anti-4-phenoxyphenylaminoglyoxime and its some transition metal complexes: Spectral, DFT, electrochemical and anticancer activity studies

      2020, Journal of Molecular Structure
      Citation Excerpt :

      Exploring the newly synthesized compounds and improving their biological activities by metal complexes appears to be crucial strategy to develop novel anticancer drugs. Recent evidences suggest that new oxime-based compounds could be evaluated as therapeutic agents for cancer therapy [24–29]. In light of this facts, at present study, we evauated the cytotoxic effects of our novel oxime ligand (LH2) and its metal complexes; Cu(LH)2 and Ni(LH)2, on MCF7 breast cancer cell line.

    • Solute carrier transporters: the metabolic gatekeepers of immune cells

      2020, Acta Pharmaceutica Sinica B
      Citation Excerpt :

      While GLUT6 was previously reported to mediate glucose uptake in endometrial cancer cells65, at least in macrophages, the lysosomally located GLUT6 is not a true glucose transporter, and its physiological roles in immune cells still need to be clarified further64. The information reviewed above glucose transporters involved in immune cells are summarized in Table 166–86,87-119. Glutamine is one of the most abundant amino acids in circulation.

    • Glucose transport

      2019, Stress: Physiology, Biochemistry, and Pathology Handbook of Stress Series, Volume 3
    • Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer cells

      2017, Archives of Biochemistry and Biophysics
      Citation Excerpt :

      Therefore, Glut1 represents a potential therapeutic target for many cancers. Recent studies have focused on inhibiting Gluts to decrease cancer cell growth [22–25]. Basal-like breast cancers generally lack estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2) on clinical assays and commonly referred to as “triple-negative” [26].

    View all citing articles on Scopus
    View full text